Literature DB >> 33961025

Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series.

Matthew Shneyderman1, Shivani Ahlawat2, Lisa Christopher-Stine3, Julie J Paik3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33961025      PMCID： PMC8566241          DOI： 10.1093/rheumatology/keab421

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  5 in total

1.  Calcinosis cutis complicating adult-onset dermatomyositis.

Authors:  Sarah Weinel; Jeffrey P Callen
Journal:  Arch Dermatol       Date:  2004-03

2.  Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib.

Authors:  Sara Sabbagh; Adriana Almeida de Jesus; SuJin Hwang; Hye Sun Kuehn; Hanna Kim; Lawrence Jung; Ruy Carrasco; Sergio Rosenzweig; Raphaela Goldbach-Mansky; Lisa G Rider
Journal:  Brain       Date:  2019-11-01       Impact factor: 13.501

3.  Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification.

Authors:  S L Bowyer; C E Blane; D B Sullivan; J T Cassidy
Journal:  J Pediatr       Date:  1983-12       Impact factor: 4.406

4.  Patterns of calcification in childhood dermatomyositis.

Authors:  C E Blane; S J White; E M Braunstein; S L Bowyer; D B Sullivan
Journal:  AJR Am J Roentgenol       Date:  1984-02       Impact factor: 3.959

5.  Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients.

Authors:  Julie J Paik; Livia Casciola-Rosen; Joseph Yusup Shin; Jemima Albayda; Eleni Tiniakou; Doris G Leung; Laura Gutierrez-Alamillo; Jamie Perin; Liliana Florea; Corina Antonescu; Sherry G Leung; Grazyna Purwin; Andrew Koenig; Lisa Christopher-Stine
Journal:  Arthritis Rheumatol       Date:  2021-03-24       Impact factor: 10.995
  5 in total
  5 in total

Review 1.  Subcutaneous calcinosis: Is it different between systemic sclerosis and dermatomyositis?

Authors:  Antonia Valenzuela; Lorinda Chung
Journal:  J Scleroderma Relat Disord       Date:  2021-10-28

Review 2.  Calcinosis in systemic sclerosis.

Authors:  Srijana Davuluri; Christian Lood; Lorinda Chung
Journal:  Curr Opin Rheumatol       Date:  2022-08-19       Impact factor: 4.941

Review 3.  A glance into the future of myositis therapy.

Authors:  Ilaria Chiapparoli; Claudio Galluzzo; Carlo Salvarani; Nicolò Pipitone
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-05-24       Impact factor: 3.625

Review 4.  Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature.

Authors:  Kareem G Elhage; Raymond Zhao; Mio Nakamura
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-09-08

Review 5.  JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology.

Authors:  Meredyth G Ll Wilkinson; Claire T Deakin; Charalampia Papadopoulou; Despina Eleftheriou; Lucy R Wedderburn
Journal:  Pediatr Rheumatol Online J       Date:  2021-09-25       Impact factor: 3.054
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.